大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权

保观2025-09-29

保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。此次交易体现了上海国资平台的协同作战优势，上实集团与...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2571800933?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-09-29 12:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2571800933","market":"hk","top_or_hot":-1,"title":"大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权","media":"保观","content":"<div>\n<p>保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。此次交易体现了上海国资平台的协同作战优势，上实集团与...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n大健康行业周报 |13亿，“中国美敦力”完成交割；东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-09-29 12:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b><strong>保观</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。此次交易体现了上海国资平台的协同作战优势，上实集团与...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1251922891.USD","symbol_name":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","article_id":"2571800933","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250929123929a44b6c21&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2571800933","pubTimestamp":1759118650,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1251922891.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) ACC","BK1191":"制药","BK1593":"医美概念股","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","LU1023057109.AUD":"BGF CHINA \"A2\" (AUDHDG) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","01276":"恒瑞医药","IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","03692":"翰森制药","LU1303224171.USD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (USD) INC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","BK1515":"抗疫概念","LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","LU1719994722.HKD":"NINETY ONE GSF ALL CHINA EQUITY \"A\" (HKD) ACC","BK1606":"中医药概念","BK1570":"华润系","03320":"华润医药","02196":"复星医药","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","01177":"中国生物制药","BK1197":"保健护理产品经销商","LU2039709279.SGD":"MANULIFE GF DRAGON GROWTH \"AA\" (SGDHDG) INC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","06160":"百济神州","LU0359201885.HKD":"BGF CHINA \"A2\" (HKD) ACC","00570":"中国中药","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","01093":"石药集团","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","BK1500":"做空集合股","LU1328277881.USD":"MANULIFE GF DRAGON GROWTH FUND \"AA\" (USD) INC","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","SBHMY":"中国生物制药ADR","LU0588546209.SGD":"Eastspring Investments - China Equity Fund AS SGD","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","03933":"联邦制药","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","00874":"白云山"},"translate_title":"Big Health Industry Weekly Report | 1.3 billion, \"China Medtronic\" completed delivery; Dongxing Medical: Plans to purchase 90% equity of Wuhan Yijiabao by paying cash","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00874":1,"01177":1,"01276":1,"02196":1,"SBHMY":0.9,"03320":1,"00570":1,"01093":1,"03933":1,"03692":1,"06160":1},"content_text":"保观 |聚焦保险创新国内篇行业动态13亿，“中国美敦力”完成交割近日，上海生物医药并购基金携手浦东创投集团旗下引领区基金，完成收购日本大冢集团所持微创医疗股份的交割，交易金额达13亿元人民币，上海生物医药并购基金成为微创医疗重要战略股东，持股约7.3%。此次交割完成后，被视为“中国美敦力”的微创医疗股价在港股市场表现活跃，市值突破200亿港元。此次交易体现了上海国资平台的协同作战优势，上实集团与浦东创投集团将发挥国有资本核心作用，助力微创医疗在全球化布局与创新研发上实现突破。此次交割是对7月25日交易公告的实质性推进，采用“国资战略入股 + 原有股东增持”模式，保障了企业发展的稳定性。（来源：器械之家）东星医疗：拟以支付现金方式购买武汉医佳宝90%的股权9月26日，东星医疗发布公告称，公司计划以现金支付方式收购武汉医佳宝生物材料有限公司90%的股权，此交易预计构成重大资产重组。目前，该交易尚处于初步筹划阶段，交易方案和条款仍需进一步论证与协商，且上市公司及标的公司均需履行必要的内外部决策和审批程序，存在未能通过审批的风险。东星医疗表示，将严格按照相关法律法规及《公司章程》的规定，履行决策审批程序和信息披露义务。不过，由于交易存在不确定性，外部环境变化可能导致交易条件改变，进而可能使交易终止。（来源：新浪财经）12亿！老牌CRO企业二次收购2025年9月25日，北京阳光诺和药物研究股份有限公司（以下简称“阳光诺和”）发布公告称，公司拟通过发行股份及可转换公司债券方式购买江苏朗研生命科技控股有限公司（以下简称“朗研生命”）100%股权，并向不超过35名特定投资者发行股份募集配套资金。（来源：动脉网）《2025年中国医疗云影像行业白皮书》发布9月27日，在2号馆T04展台，由（复旦大学）上海市影像医学研究所、中国信息协会医疗卫生和健康产业分会、尚普咨询集团、动脉网联合发布，汇聚行业专家作为顾问专家组编撰的《2025年中国医疗云影像行业白皮书》（以下简称：白皮书）举行了盛大的发布会，引发行业高度关注。（来源：动脉网）融资信息神拓生物完成数千万元天使+轮融资神拓生物技术（杭州）有限公司（以下简称“神拓生物”）完成天使+轮融资，融资总额达数千万元。本轮融资由冷杉溪资本独家投资，所募资金将用于公司全球领先的慢病毒基因治疗管线的开发。（来源：动脉网）昂泰微精完成数亿元B轮融资深耕超显微、高精度手术机器人的昂泰微精医疗科技（上海）有限公司（以下简称“昂泰微精”）近日宣布完成数亿元B轮融资。本轮融资由产业资本与知名投资机构共同参与，春木资本担任独家财务顾问。本轮资金将主要用于巩固核心产品技术优势、完善显微机器人系列产品生态、加速临床注册进程以及推动国际化市场布局。（来源：动脉网）透彻未来完成 A++ 轮融资全球智慧病理领域的领军企业——透彻未来，正式对外宣布成功完成A++轮融资，本轮融资由道合科技投资领投。这一里程碑式的成就，彰显了透彻未来在病理大模型临床应用的深厚实力以及在数智化建设中的突出贡献，标志着其在推动全球病理数智化进程中又迈出了坚实的一步。一苇资本担任此次交易独家财务顾问。（来源：动脉网）慧观生物完成Pre-A+轮融资近日，武汉慧观生物科技有限公司（以下简称 “慧观生物”）完成 Pre-A+ 轮融资，本轮投资由光谷产投和长江创投联合领投，光谷金控共同投资。融资资金主要用于产品研发、市场推广及团队扩充等，进一步巩固公司在高端生物医学影像领域的领先地位。（来源：动脉网）行业数据港股前十大制药企业共掏出逾200亿元搞研发根据半年报，营收规模居前的十大企业分别是华润医药（03320.HK）、白云山（00874.HK）、复星医药（02196.HK）、中国生物制药（01177.HK）、百济神州（06160.HK）、恒瑞医药（01276.HK）、石药集团（01093.HK）、联邦制药（03933.HK）、中国中药（00570.HK）、翰森制药（03692.HK），这些企业今年上半年研发费用的投入累计达到218.25亿元，归属于母公司股东的净利润总和为221.03亿元。（来源：米内网）监管动态国家医保局启动医保基金管理专项整治国家医保局25日发布《国家医疗保障局办公室关于开展医保基金管理突出问题专项整治“百日行动”的通知》提出，自即日起至2025年12月31日，在全国范围开展医保基金管理突出问题专项整治“百日行动”。国家医保局表示，“百日行动”是医保基金管理突出问题专项整治“突击战”的重要行动安排，坚决以“零容忍、不松劲”的较真态度和“敢啃硬骨头”的攻坚魄力，依法依规、严查严打欺诈骗保，力争通过“百日行动”基本肃清两定机构倒卖医保回流药违法行为。（来源：米内网）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2571800933","isCrawlerRequest":true}